Serological Response to BNT162b2 and ChAdOx1 nCoV-19 Vaccines in Patients with Inflammatory Bowel Disease on Biologic Therapies
<b>Introduction:</b> The immunogenicity of SARS-CoV-2 vaccines in patients with inflammatory bowel disease (IBD) on biologic therapies is not well studied. The goal of this study was to measure the serological response to BNT162b2 and ChAdOx1 nCoV-19 vaccines in patients with IBD receivi...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-12-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/9/12/1471 |
| _version_ | 1797500017698668544 |
|---|---|
| author | Mohammad Shehab Fatema Alrashed Ahmad Alfadhli Khazna Alotaibi Abdullah Alsahli Hussain Mohammad Preethi Cherian Irina Al-Khairi Thangavel Alphonse Thanaraj Arshad Channanath Hamad Ali Mohamed Abu-Farha Jehad Abubaker Fahd Al-Mulla |
| author_facet | Mohammad Shehab Fatema Alrashed Ahmad Alfadhli Khazna Alotaibi Abdullah Alsahli Hussain Mohammad Preethi Cherian Irina Al-Khairi Thangavel Alphonse Thanaraj Arshad Channanath Hamad Ali Mohamed Abu-Farha Jehad Abubaker Fahd Al-Mulla |
| author_sort | Mohammad Shehab |
| collection | DOAJ |
| description | <b>Introduction:</b> The immunogenicity of SARS-CoV-2 vaccines in patients with inflammatory bowel disease (IBD) on biologic therapies is not well studied. The goal of this study was to measure the serological response to BNT162b2 and ChAdOx1 nCoV-19 vaccines in patients with IBD receiving different biologic therapies. <b>Methods:</b> We performed a multi-center prospective study between 1 August 2021 and 15 September 2021. We measured the seropositivity of SARS-CoV-2 antibodies (SARS-CoV-2 IgG) and neutralizing antibody concentrations in patients with IBD receiving biologic therapies 4–10 weeks after their second dose or 3–6 weeks after their first dose of BNT162b2 or ChAdOx1 nCoV-19 vaccines. <b>Results:</b> A total of 126 patients were enrolled (mean age, 31 years; 60% male; 71% Crohn’s disease, 29% ulcerative colitis). Of these, 92 patients were vaccinated with the BNT162b2 vaccine (73%) and 34 patients with the ChAdOx1 nCoV-19 vaccine (27%). In patients being treated with infliximab and adalimumab, the proportion of patients who achieved positive anti-SARS-CoV-2 IgG antibody levels after receiving two doses of the vaccine were 44 out of 59 patients (74.5%) and 13 out of 16 patients (81.2%), respectively. In contrast, of those receiving ustekinumab and vedolizumab, the proportion of patients who achieved positive anti-SARS-CoV-2 IgG antibody levels after receiving two doses of the vaccine were 100% and 92.8%, respectively. In patients receiving infliximab and adalimumab, the proportion of patients who had positive anti-SARS-CoV-2 neutralizing antibody levels after two-dose vaccination was 40 out of 59 patients (67.7%) and 14 out 16 patients (87.5%), respectively. On the other hand, the proportion of patients who had positive anti-SARS-CoV-2 neutralizing antibody levels were 12 out of 13 patients (92.3%) and 13 out of 14 patients (92.8%) in patients receiving ustekinumab and vedolizumab, respectively. <b>Conclusions:</b> The majority of patients with IBD who were on infliximab, adalimumab, and vedolizumab seroconverted after two doses of SARS-CoV-2 vaccination. All patients on ustekinumab seroconverted after two doses of SARS-CoV-2 vaccine. The BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines are both likely to be effective after two doses in patients with IBD on biologics. Larger follow-up studies are needed to evaluate if decay of antibodies occurs over time. |
| first_indexed | 2024-03-10T03:55:47Z |
| format | Article |
| id | doaj.art-187cb4823865465cb89af316c98e9ac4 |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-10T03:55:47Z |
| publishDate | 2021-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-187cb4823865465cb89af316c98e9ac42023-11-23T10:54:49ZengMDPI AGVaccines2076-393X2021-12-01912147110.3390/vaccines9121471Serological Response to BNT162b2 and ChAdOx1 nCoV-19 Vaccines in Patients with Inflammatory Bowel Disease on Biologic TherapiesMohammad Shehab0Fatema Alrashed1Ahmad Alfadhli2Khazna Alotaibi3Abdullah Alsahli4Hussain Mohammad5Preethi Cherian6Irina Al-Khairi7Thangavel Alphonse Thanaraj8Arshad Channanath9Hamad Ali10Mohamed Abu-Farha11Jehad Abubaker12Fahd Al-Mulla13Division of Gastroenterology, Department of Internal Medicine, Mubarak Alkabeer University Hospital, Kuwait University, Aljabreyah 47060, KuwaitDepartment of Pharmacy Practice, Faculty of Pharmacy, Health Sciences Center (HSC), Kuwait University, Jabriya 13110, KuwaitDivision of Gastroenterology, Department of Internal Medicine, Mubarak Alkabeer University Hospital, Kuwait University, Aljabreyah 47060, KuwaitDivision of Gastroenterology, Department of Internal Medicine, Mubarak Alkabeer University Hospital, Kuwait University, Aljabreyah 47060, KuwaitDivision of Gastroenterology, Department of Internal Medicine, Mubarak Alkabeer University Hospital, Kuwait University, Aljabreyah 47060, KuwaitDivision of Gastroenterology, Department of Internal Medicine, Mubarak Alkabeer University Hospital, Kuwait University, Aljabreyah 47060, KuwaitDepartment of Biochemistry and Molecular Biology, Dasman Diabetes Institute (DDI), Dasman 15462, KuwaitDepartment of Biochemistry and Molecular Biology, Dasman Diabetes Institute (DDI), Dasman 15462, KuwaitDepartment of Genetics and Bioinformatics, Dasman Diabetes Institute (DDI), Dasman 15462, KuwaitDepartment of Genetics and Bioinformatics, Dasman Diabetes Institute (DDI), Dasman 15462, KuwaitDepartment of Genetics and Bioinformatics, Dasman Diabetes Institute (DDI), Dasman 15462, KuwaitDepartment of Biochemistry and Molecular Biology, Dasman Diabetes Institute (DDI), Dasman 15462, KuwaitDepartment of Biochemistry and Molecular Biology, Dasman Diabetes Institute (DDI), Dasman 15462, KuwaitDepartment of Genetics and Bioinformatics, Dasman Diabetes Institute (DDI), Dasman 15462, Kuwait<b>Introduction:</b> The immunogenicity of SARS-CoV-2 vaccines in patients with inflammatory bowel disease (IBD) on biologic therapies is not well studied. The goal of this study was to measure the serological response to BNT162b2 and ChAdOx1 nCoV-19 vaccines in patients with IBD receiving different biologic therapies. <b>Methods:</b> We performed a multi-center prospective study between 1 August 2021 and 15 September 2021. We measured the seropositivity of SARS-CoV-2 antibodies (SARS-CoV-2 IgG) and neutralizing antibody concentrations in patients with IBD receiving biologic therapies 4–10 weeks after their second dose or 3–6 weeks after their first dose of BNT162b2 or ChAdOx1 nCoV-19 vaccines. <b>Results:</b> A total of 126 patients were enrolled (mean age, 31 years; 60% male; 71% Crohn’s disease, 29% ulcerative colitis). Of these, 92 patients were vaccinated with the BNT162b2 vaccine (73%) and 34 patients with the ChAdOx1 nCoV-19 vaccine (27%). In patients being treated with infliximab and adalimumab, the proportion of patients who achieved positive anti-SARS-CoV-2 IgG antibody levels after receiving two doses of the vaccine were 44 out of 59 patients (74.5%) and 13 out of 16 patients (81.2%), respectively. In contrast, of those receiving ustekinumab and vedolizumab, the proportion of patients who achieved positive anti-SARS-CoV-2 IgG antibody levels after receiving two doses of the vaccine were 100% and 92.8%, respectively. In patients receiving infliximab and adalimumab, the proportion of patients who had positive anti-SARS-CoV-2 neutralizing antibody levels after two-dose vaccination was 40 out of 59 patients (67.7%) and 14 out 16 patients (87.5%), respectively. On the other hand, the proportion of patients who had positive anti-SARS-CoV-2 neutralizing antibody levels were 12 out of 13 patients (92.3%) and 13 out of 14 patients (92.8%) in patients receiving ustekinumab and vedolizumab, respectively. <b>Conclusions:</b> The majority of patients with IBD who were on infliximab, adalimumab, and vedolizumab seroconverted after two doses of SARS-CoV-2 vaccination. All patients on ustekinumab seroconverted after two doses of SARS-CoV-2 vaccine. The BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines are both likely to be effective after two doses in patients with IBD on biologics. Larger follow-up studies are needed to evaluate if decay of antibodies occurs over time.https://www.mdpi.com/2076-393X/9/12/1471IBDCOVID-19vaccineimmunogenicityinfliximabadalimumab |
| spellingShingle | Mohammad Shehab Fatema Alrashed Ahmad Alfadhli Khazna Alotaibi Abdullah Alsahli Hussain Mohammad Preethi Cherian Irina Al-Khairi Thangavel Alphonse Thanaraj Arshad Channanath Hamad Ali Mohamed Abu-Farha Jehad Abubaker Fahd Al-Mulla Serological Response to BNT162b2 and ChAdOx1 nCoV-19 Vaccines in Patients with Inflammatory Bowel Disease on Biologic Therapies Vaccines IBD COVID-19 vaccine immunogenicity infliximab adalimumab |
| title | Serological Response to BNT162b2 and ChAdOx1 nCoV-19 Vaccines in Patients with Inflammatory Bowel Disease on Biologic Therapies |
| title_full | Serological Response to BNT162b2 and ChAdOx1 nCoV-19 Vaccines in Patients with Inflammatory Bowel Disease on Biologic Therapies |
| title_fullStr | Serological Response to BNT162b2 and ChAdOx1 nCoV-19 Vaccines in Patients with Inflammatory Bowel Disease on Biologic Therapies |
| title_full_unstemmed | Serological Response to BNT162b2 and ChAdOx1 nCoV-19 Vaccines in Patients with Inflammatory Bowel Disease on Biologic Therapies |
| title_short | Serological Response to BNT162b2 and ChAdOx1 nCoV-19 Vaccines in Patients with Inflammatory Bowel Disease on Biologic Therapies |
| title_sort | serological response to bnt162b2 and chadox1 ncov 19 vaccines in patients with inflammatory bowel disease on biologic therapies |
| topic | IBD COVID-19 vaccine immunogenicity infliximab adalimumab |
| url | https://www.mdpi.com/2076-393X/9/12/1471 |
| work_keys_str_mv | AT mohammadshehab serologicalresponsetobnt162b2andchadox1ncov19vaccinesinpatientswithinflammatoryboweldiseaseonbiologictherapies AT fatemaalrashed serologicalresponsetobnt162b2andchadox1ncov19vaccinesinpatientswithinflammatoryboweldiseaseonbiologictherapies AT ahmadalfadhli serologicalresponsetobnt162b2andchadox1ncov19vaccinesinpatientswithinflammatoryboweldiseaseonbiologictherapies AT khaznaalotaibi serologicalresponsetobnt162b2andchadox1ncov19vaccinesinpatientswithinflammatoryboweldiseaseonbiologictherapies AT abdullahalsahli serologicalresponsetobnt162b2andchadox1ncov19vaccinesinpatientswithinflammatoryboweldiseaseonbiologictherapies AT hussainmohammad serologicalresponsetobnt162b2andchadox1ncov19vaccinesinpatientswithinflammatoryboweldiseaseonbiologictherapies AT preethicherian serologicalresponsetobnt162b2andchadox1ncov19vaccinesinpatientswithinflammatoryboweldiseaseonbiologictherapies AT irinaalkhairi serologicalresponsetobnt162b2andchadox1ncov19vaccinesinpatientswithinflammatoryboweldiseaseonbiologictherapies AT thangavelalphonsethanaraj serologicalresponsetobnt162b2andchadox1ncov19vaccinesinpatientswithinflammatoryboweldiseaseonbiologictherapies AT arshadchannanath serologicalresponsetobnt162b2andchadox1ncov19vaccinesinpatientswithinflammatoryboweldiseaseonbiologictherapies AT hamadali serologicalresponsetobnt162b2andchadox1ncov19vaccinesinpatientswithinflammatoryboweldiseaseonbiologictherapies AT mohamedabufarha serologicalresponsetobnt162b2andchadox1ncov19vaccinesinpatientswithinflammatoryboweldiseaseonbiologictherapies AT jehadabubaker serologicalresponsetobnt162b2andchadox1ncov19vaccinesinpatientswithinflammatoryboweldiseaseonbiologictherapies AT fahdalmulla serologicalresponsetobnt162b2andchadox1ncov19vaccinesinpatientswithinflammatoryboweldiseaseonbiologictherapies |